Switzerland: KKR agrees to acquire Biosynth Carbosynth from Armira

Global investment firm, KKR, has agreed to acquire Biosynth Carbosynth, a leading life sciences reagents and custom synthesis and manufacturing services company, from Armira, a Munich-based investor, and CEO Urs Spitz. Spitz and senior managers of the company will retain a significant ownership stake and will continue to lead the company as it embarks on…

You must be a HMI Subscriber to view this content.

Subscribe Now »